AstraZeneca PLC vs Sanofi: A Decade of SG&A Expense Trends

In the competitive landscape of the pharmaceutical industry, AstraZeneca PLC and Sanofi have been pivotal players. Over the past decade, from 2014 to 2023, their Selling, General, and Administrative (SG&A) expenses have shown intriguing trends. AstraZeneca's SG&A expenses have surged by approximately 35%, peaking in 2022 with a notable 19% increase from the previous year. In contrast, Sanofi's expenses have remained relatively stable, with a modest 13% increase over the same period.

This divergence highlights AstraZeneca's aggressive expansion and marketing strategies, while Sanofi maintains a steady course. The data underscores the strategic differences between these pharmaceutical giants, reflecting their unique approaches to market challenges and opportunities. As the industry evolves, these trends offer valuable insights into the financial strategies shaping the future of healthcare.